文献速递前列腺癌

为改善放疗结局的根治性前列腺切除术后专用影像试验(DIPPER)方案:根治性前列腺切除术后低危生化复发患者挽救性放疗与监测对比的多中心随机试验

The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
PubMed 文献 · BJU Int · 2023-09-14

DIPPER是一项开放标签、多中心、随机II期试验,计划从五家澳大利亚中心招募100例根治性前列腺切除术后低危生化复发且PSMA-PET/CT未见明确复发灶的患者,1:1随机接受挽救性放疗或监测,主要终点为3年无事件生存,入组始于2023年5月。

要点

  • 低危定义:PSA 0.2-0.5 ng/mL、ISUP分级分组≤2且PSA倍增时间>12个月。
  • 随机分组为挽救性放疗或监测,不允许使用雄激素剥夺治疗。
  • 主要终点为3年无事件生存,事件包括PSA复发、影像学转移或启动系统/其他挽救治疗。

核心结论

  • 对于根治性前列腺切除术后PSA复发且PSMA-PET/CT未见明确复发灶的低危患者,早期前列腺床±盆腔淋巴结挽救性放疗相较于监测的疗效尚不明确。

研究设计与样本

  • DIPPER为开放标签、多中心、随机II期试验,计划从五家澳大利亚中心招募100例参与者,1:1随机分配至挽救性放疗或监测,入组始于2023年5月。

主要发现

  • 主要终点为3年无事件生存,事件包括PSA复发(PSA较基线升高≥0.2 ng/mL)、影像学转移证据或启动系统或其他挽救治疗。
  • 次要终点包括患者报告结局、治疗模式、参与者认知和成本效果。
  • 参与者将接受长达36个月的每6个月临床评估。
  • 不允许使用雄激素剥夺治疗。

关键数值与推荐

  • Eligible participants have PSA recurrence after radical prostatectomy defined by serum PSA level of 0.2-0.5 ng/mL, deemed low risk according to modified European Association of Urology biochemical recurrence risk criteria (International Society for Urological Pathology Grade Group ≤2, PSA doubling time >12 months), with no definite/probable recurrent prostate cancer on PSMA-PET/CT.

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Salvage radiation therapy (SRT) and surveillance for low-risk prostate-specific antigen (PSA) recurrence have competing risks and benefits. The efficacy of early SRT to the prostate bed with or without pelvic lymph nodes compared to surveillance in patients with PSA recurrence after radical prostatectomy and no identifiable recurrent disease evident on prostate specific membrane antigen-positron emission tomography/computer tomography (PSMA-PET/CT) is unknown. STUDY DESIGN: The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) is an open-label, multicentre, randomised Phase II trial. ENDPOINTS: The primary endpoint is 3-year event-free survival, with events comprising one of PSA recurrence (PSA ≥0.2 ng/mL higher than baseline), radiological evidence of metastatic disease, or initiation of systemic or other salvage treatments. Secondary endpoints include patient-reported outcomes, treatment patterns, participant perceptions, and cost-effectiveness. ELIGIBILITY CRITERIA: Eligible participants have PSA recurrence of prostate cancer after radical prostatectomy, defined by serum PSA level of 0.2-0.5 ng/mL, deemed low risk according to modified European Association of Urology biochemical recurrence risk criteria (International Society for Urological Pathology Grade Group ≤2, PSA doubling time >12 months), with no definite/probable recurrent prostate cancer on PSMA-PET/CT. PATIENTS AND METHODS: A total of 100 participants will be recruited from five Australian centres and randomised 1:1 to SRT or surveillance. Participants will undergo 6-monthly clinical evaluation for up to 36 months. Androgen-deprivation therapy is not permissible. Enrolment commenced May 2023. TRIAL REGISTRATION: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ACTRN: ACTRN12622001478707).

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Roberts MJ, Conduit C, Davis ID, et al. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy. BJU Int. 2023. PMID: 37604702. doi:10.1111/bju.16158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。